title: REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinson's disease.
abstract: The recently described intranigral rotenone model of Parkinson's disease (PD) in rodents provides an interesting model for studying mechanisms of toxin-induced dopaminergic neuronal injury. The relevance of this model remains unexplored with regard to sleep disorders that occur in PD. On this basis, the construction of a PD model depicting several behavioral and neurochemical alterations related to sleep would be helpful in understanding the association between PD and sleep regulation. We performed bilateral intranigral injections of rotenone (12 μg) on day 0 and the open-field test initially on day 20 after rotenone. Acquisition phase of the object-recognition test, executed also during day 20, was followed by an exact period of 24 hr of rapid eye movement (REM) sleep deprivation (REMSD; day 21). In the subsequent day (22), the rats were re-exposed to the open-field test and to the object-recognition test (choice phase). After the last session of behavioral tests, the rat brains were immediately dissected, and their striata were collected for neurochemical purposes. We observed that a brief exposure to REMSD was able to impair drastically the object-recognition test, similarly to a nigrostriatal lesion promoted by intranigral rotenone. However, the combination of REMSD and rotenone surprisingly did not inflict memory impairment, concomitant with a moderate compensatory mechanism mediated by striatal dopamine release. In addition, we demonstrated the existence of changes in serotonin and noradrenaline neurotransmissions within the striatum mostly as a function of REMSD and REMSD plus rotenone, respectively.
authors.affiliation: Laboratório de Neurofisiologia, Departamento de Fisiologia, Universidade Federal do Paraná, Curitiba, Paraná, Brasil.
authors.forename: Ana Carolina D
authors.initials: AC
authors.lastname: Dos Santos
authors.forename: Marcela Alexandra V
authors.initials: MA
authors.lastname: Castro
authors.forename: Elis Angela K
authors.initials: EA
authors.lastname: Jose
authors.forename: Ana Márcia
authors.initials: AM
authors.lastname: Delattre
authors.forename: Patrícia A
authors.initials: PA
authors.lastname: Dombrowski
authors.forename: Claudio
authors.initials: C
authors.lastname: Da Cunha
authors.forename: Anete C
authors.initials: AC
authors.lastname: Ferraz
authors.forename: Marcelo M S
authors.initials: MM
authors.lastname: Lima
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D003071:Cognition; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D004195:Disease Models, Animal; D007276:Injections, Intraventricular; D007858:Learning / Q000502:physiology; D008297:Male; D008568:Memory / Q000502:physiology; D020734:Parkinsonian Disorders / Q000378:metabolism / Q000503:physiopathology*; D051381:Rats; D017208:Rats, Wistar; D012402:Rotenone / Q000008:administration & dosage / Q000633:toxicity; D012892:Sleep Deprivation / Q000378:metabolism / Q000503:physiopathology*; D014475:Uncoupling Agents / Q000008:administration & dosage / Q000633:toxicity
chemical_list: D014475:Uncoupling Agents; D012402:Rotenone
keywords: Parkinson's disease; REM sleep deprivation; dopamine; intranigral; rotenone; substantia nigra pars compacta